Free Trial

Pfizer (PFE) Stock Forecast & Price Target

Pfizer logo
$27.36 +0.29 (+1.05%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$27.35 -0.01 (-0.05%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
12
Buy
6

Based on 19 Wall Street analysts who have issued ratings for Pfizer in the last 12 months, the stock has a consensus rating of "Hold." Out of the 19 analysts, 1 has given a sell rating, 12 have given a hold rating, 4 have given a buy rating, and 2 have given a strong buy rating for PFE.

Consensus Price Target

$28.41
3.83% Upside
According to the 19 analysts' twelve-month price targets for Pfizer, the average price target is $28.41. The highest price target for PFE is $33.00, while the lowest price target for PFE is $23.00. The average price target represents a forecasted upside of 3.83% from the current price of $27.37.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for PFE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pfizer and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PFE Analyst Ratings Over Time

TypeCurrent Forecast
10/4/24 to 10/4/25
1 Month Ago
9/4/24 to 9/4/25
3 Months Ago
7/6/24 to 7/6/25
1 Year Ago
10/5/23 to 10/4/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
3 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
Hold
12 Hold rating(s)
11 Hold rating(s)
13 Hold rating(s)
8 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$28.41$28.12$28.55$34.54
Forecasted Upside3.83% Upside14.74% Upside12.20% Upside20.85% Upside
Consensus RatingHoldHoldHoldModerate Buy

PFE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PFE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Pfizer Stock vs. The Competition

TypePfizerMedical CompaniesS&P 500
Consensus Rating Score
2.37
2.33
2.51
Consensus RatingHoldHoldModerate Buy
Predicted Upside3.83% Upside1,395.18% Upside10.48% Upside
News Sentiment Rating
Positive News

See Recent PFE News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/3/2025Bank of America
4 of 5 stars
Tim Anderson
Tim Anderson
Not Rated
Boost TargetNeutral$28.00 ➝ $30.00+10.80%
10/1/2025UBS Group
4 of 5 stars
Tim Anderson
Not Rated
Reiterated RatingNeutral$28.00+6.48%
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingHold (C-)
8/6/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$25.00 ➝ $26.00+8.57%
8/6/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$32.00 ➝ $33.00+37.75%
5/29/2025Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetHold$28.00 ➝ $25.00+6.66%
5/21/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$32.00 ➝ $33.00+43.11%
5/19/2025HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$27.00 ➝ $26.00+12.99%
4/30/2025Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetUnderperform$22.00 ➝ $23.00-5.78%
4/30/2025Redburn Atlantic
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetNeutral$29.00 ➝ $27.00+10.61%
4/30/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetMarket Perform$28.00 ➝ $26.00+6.51%
4/30/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$25.00 ➝ $27.00+10.61%
4/22/2025TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetHold$32.00 ➝ $28.00+24.22%
4/22/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweightNeutral$24.00+8.74%
4/17/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower Target$36.00 ➝ $30.00+35.57%
3/18/2025Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
3/10/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
12/18/2024Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$36.00 ➝ $32.00+21.72%
10/30/2024Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$32.00+7.89%
8/7/2024Daiwa America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeModerate BuyStrong-Buy
8/7/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeNeutralOutperform$28.00 ➝ $34.00+14.21%
7/31/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetEqual Weight$30.00 ➝ $32.00+4.51%
7/31/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetEqual Weight$28.00 ➝ $30.00-3.23%
3/22/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold
10/16/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetNeutral$36.00 ➝ $34.00+0.71%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:43 AM ET.


Should I Buy Pfizer Stock? PFE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 30, 2025. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

Pfizer
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Pfizer Inc.:

  • The company recently reported earnings per share of $0.78, significantly exceeding analysts' expectations, indicating strong financial performance.
  • Pfizer Inc. has a solid market capitalization of approximately $135.54 billion, reflecting its stability and potential for growth in the biopharmaceutical sector.
  • With a current stock price around $24.54, it presents an attractive entry point for investors looking for value in the market.
  • The company has shown a year-over-year revenue increase of 10.3%, suggesting robust demand for its products and effective business strategies.
  • Pfizer Inc. has a favorable debt-to-equity ratio of 0.65, indicating a balanced approach to leveraging debt while maintaining financial health.

Pfizer
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Pfizer Inc. for these reasons:

  • Despite recent successes, the stock has been rated as "Hold" by several analysts, suggesting that there may be limited upside potential in the near term.
  • The quick ratio of 0.85 indicates that the company may face challenges in meeting its short-term liabilities, which could raise concerns for investors.
  • Pfizer Inc. has a relatively low P/E ratio of 12.68, which may suggest that the stock is undervalued, but could also indicate market skepticism about future growth.
  • Recent analyst reports have shown mixed ratings, with some firms downgrading their outlook, which could create uncertainty for potential investors.
  • The company operates in a highly competitive biopharmaceutical market, which may pose risks to its market share and profitability in the long run.

PFE Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Pfizer is $28.41, with a high forecast of $33.00 and a low forecast of $23.00.

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last twelve months. There is currently 1 sell rating, 12 hold ratings, 4 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PFE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares.

According to analysts, Pfizer's stock has a predicted upside of 3.83% based on their 12-month stock forecasts.

Pfizer has been rated by research analysts at Bank of America, Citigroup, Morgan Stanley, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Pfizer more than other "medical" companies. The consensus rating score for Pfizer is 2.37 while the average consensus rating score for "medical" companies is 2.33. Learn more on how PFE compares to other companies.


This page (NYSE:PFE) was last updated on 10/4/2025 by MarketBeat.com Staff
From Our Partners